Trial comparing treatments for IDH-Wildtype Glioblastoma
Official title The Feasibility and Efficacy of Dose Timing (Morning vs Evening) of Temozolomide in the Treatment of Glioblastoma
ClinicalTrials.gov ID: NCT06850766
What this study is testing
- What it's testing
- The study wants to see if patients can reliably take temozolomide at a set time of day and to check safety, quality of life, and other effects. It will also look at how well the trial can recruit participants.
- Who it's for
- Adults who have newly diagnosed IDH‑wildtype glioblastoma and have finished surgery and radiation.
- What's involved
- Participants are randomly assigned to take temozolomide either in the morning or in the evening, record each dose in a diary, and wear a wrist‑worn activity monitor during the first treatment cycle.
- Time commitment
- The trial follows patients for the length of their temozolomide treatment (several months) with regular clinic visits each cycle and a short monitoring period at the start.
- Time commitment: about 5 years
Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- 18 years of age or older
- Newly diagnosed IDH-wildtype glioblastoma
- Completed maximal safe brain tumor resection
- Completed post-operative brain RT
- Plan to proceed with up to 6 cycles of adjuvant TMZ within 8 weeks of completing post-operative RT
You likely can't join if
- Unable or unwilling to complete study questionnaires
- Metastatic or incurable cancer other than IDH-wild type glioblastoma
See the full eligibility criteria
- 18 years of age or older
- Newly diagnosed IDH-wildtype glioblastoma
- Completed maximal safe brain tumor resection
- Completed post-operative brain RT
- Plan to proceed with up to 6 cycles of adjuvant TMZ within 8 weeks of completing post-operative RT
- Able and willing to provide oral informed consent
- Unable or unwilling to complete study questionnaires
- Metastatic or incurable cancer other than IDH-wild type glioblastoma
The study team makes the final eligibility decision.
Where it is enrolling
- London, Ontario, Canada
- Ottawa, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The study runs about 5 years per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at London, Ontario, Canada; Ottawa, Ontario, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.